GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Men still dominating Malta’s boardrooms
The gender imbalance across Malta’s corporate landscape remains striking.
Lara Falzon appointed CEO of Yolo Group’s B2B Brands
The experienced executive said the firm has 'enormous potential for innovation, strengthening partnerships and scaling across global markets'
Why The Phoenicia Malta is the perfect setting for summer events
The Phoenicia Malta blends five-star elegance with award-winning cuisine and exceptional hospitality to create the ideal setting for group events ...
Sophie-Ann Busuttil appointed Director at Luxury Living Technologies following tragic loss of her father
For the last two years she has served as head of the group’s Luxury Living Sustainable Hospitality Company.
